Compound profile
Also known as: GLP-1 RA · Ozempic · Wegovy · Rybelsus
A GLP-1 receptor agonist (marketed as Ozempic, Wegovy, and Rybelsus) with robust clinical evidence for glycemic control and weight management. The molecule that mainstreamed this category and a reference point for understanding incretin-based approaches discussed in fitness communities.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a hormone the gut releases after eating that helps regulate insulin, appetite, and digestion. Novo Nordisk built it on the native human GLP-1 sequence, modifying it for enzymatic stability and attaching a fatty acid chain that binds albumin in the blood, extending its effect from minutes to about a week. It followed the company's earlier once-daily GLP-1 drug, liraglutide, as an attempt to reduce dosing frequency while improving efficacy.
Unlike most compounds covered on this site, semaglutide is not a research chemical. It is an FDA-approved prescription medicine sold under several brand names depending on formulation and indication: Ozempic for type 2 diabetes since 2017, Rybelsus as the first oral GLP-1 drug since 2019, and Wegovy for chronic weight management since 2021, with an oral version of Wegovy approved in late 2025. Its clinical trial program is extensive, spanning the SUSTAIN trials in diabetes, the STEP trials in obesity, and dedicated cardiovascular and kidney outcome trials.
Semaglutide is the molecule most responsible for mainstreaming GLP-1 drugs in popular conversation, and it is frequently compared against tirzepatide and referenced as the baseline against which newer investigational compounds like retatrutide are measured. Its evidence base and regulatory status are fundamentally different from the unapproved research peptides discussed elsewhere on this site, even though it gets grouped with them in casual conversation about metabolic peptides.
Mimics GLP-1 signaling to slow gastric emptying, reduce appetite, and improve insulin secretion in a glucose-dependent manner.
Semaglutide works by binding to and activating the GLP-1 receptor, the same receptor the body's own GLP-1 hormone engages after a meal. This stimulates glucose-dependent insulin release, meaning it boosts insulin mainly when blood sugar is elevated rather than constantly, suppresses glucagon, and slows gastric emptying so digestion happens more gradually. It also acts on appetite-regulating centers in the hypothalamus and brainstem, which is the main driver of the reduced food intake reported in trials.
Because semaglutide is built on the native human GLP-1 backbone rather than a non-human template, and because the amino acid substitutions and fatty acid attachment were specifically engineered to resist the enzyme DPP-4 that normally breaks GLP-1 down within minutes, it stays active in the body far longer than natural GLP-1. The albumin-binding fatty diacid chain is what allows once-weekly injections, and the oral formulations use a separate absorption-enhancing technology to get enough of the peptide across the stomach lining despite peptides generally being broken down by digestion.
Multiple large outcome and weight-management trials support efficacy for indicated uses. Cardiovascular outcome data exist for specific formulations and populations.
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
The SUSTAIN trial program reported meaningful HbA1c reductions in people with type 2 diabetes across multiple doses and formulations.
The STEP trial program reported substantial body weight loss compared with placebo in adults with obesity or overweight, which supported the Wegovy approval.
The SELECT trial, run in adults with obesity and existing cardiovascular disease but no diabetes, reported a roughly 20% reduction in major cardiovascular events versus placebo, and SUSTAIN-6 reported cardiovascular outcome findings in a diabetes population.
The FLOW trial reported slower progression of chronic kidney disease in people with type 2 diabetes and CKD, leading to an expanded kidney-related indication.
Approved pharmaceutical with known side-effect profile. Rapid weight loss can include lean mass; rebound after discontinuation is documented. Not educationally equivalent to unapproved research compounds.
Gastrointestinal side effects, nausea, vomiting, diarrhea, and constipation, are the most commonly reported issue, particularly during dose escalation, and trials generally describe them easing over time. Less common but more serious risks include gallbladder disease and, rarely, pancreatitis. Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies, a class-wide warning shared with other GLP-1 drugs, and it is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Loss of lean muscle mass alongside fat during rapid weight loss is an active area of research, and weight regain after stopping the drug is well documented in follow-up studies, which raises questions about long-term, possibly indefinite, use. Compounded, non-FDA-approved versions of semaglutide have generated their own separate safety reports tied to dosing errors and inconsistent manufacturing, distinct from the safety profile of the approved product itself. Because semaglutide is a prescription medicine with labeled indications, its use calls for medical evaluation and monitoring rather than self-directed experimentation, and that holds even though it shows up constantly in casual conversation about peptides.
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
Commonly discussed together
Semaglutide, tirzepatide, and retatrutide are commonly compared when people research metabolic and fat-loss peptide classes, from approved GLP-1/GIP medicines to investigational triple agonists.
These are distinct molecules with different approval statuses and trial populations. Comparison talk is educational, not a recommendation to obtain or combine them.
Fat loss · Metabolic
